Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

HSF1 as a Cancer Biomarker and Therapeutic Target

Heat shock factor 1 (HSF1) was discovered in 1984 as the master regulator of the heat shock response. In this classical role, HSF1 is activated following cellular stresses such as heat shock that ultimately lead to HSF1-mediated expression of heat shock proteins to protect the proteome and survive these acute stresses. However, it is now becoming clear that HSF1 also plays a significant role in several diseases, perhaps none more prominent than cancer. HSF1 appears to have a pleiotropic role in cancer by supporting multiple facets of malignancy including migration, invasion, proliferation, and cancer cell metabolism among others. Because of these functions, and others, of HSF1, it has been investigated as a biomarker for patient outcomes in multiple cancer types. HSF1 expression alone was predictive for patient outcomes in multiple cancer types but in other instances, markers for HSF1 activity were more predictive. Clearly, further work is needed to tease out which markers are most representative of the tumor promoting effects of HSF1. Additionally, there have been several attempts at developing small molecule inhibitors to reduce HSF1 activity. All of these HSF1 inhibitors are still in preclinical models but have shown varying levels of efficacy at suppressing tumor growth. The growth of research related to HSF1 in cancer has been enormous over the last decade with many new functions of HSF1 discovered along the way. In order for these discoveries to reach clinical impact, further development of HSF1 as a biomarker or therapeutic target needs to be continued

Year of Publication: 2019
Contained in: Current cancer drug targets Vol. 19, No. 7 (2019), p. 515-524
All journal articles: Search for all articles in this journal
Language: English
Contributors: Carpenter, Richard L | Author
Gökmen-Polar, Yesim
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: EMT
HSF1
Journal Article
biomarker
invasion
metastasis
migration
therapy.
ISSN: 1873-5576
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Revised 08.10.2019
published: Print
Citation Status In-Data-Review
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.2174/1568009618666181018162117
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03270nma a2200541 c 4500
001 NLM290154324
003 DE-601
005 20200220013043.0
007 cr uuu---uuuuu
008 181021s2019 000 0 eng d
024 7 |a 10.2174/1568009618666181018162117  |2 doi 
028 5 2 |a pubmed20n0965.xml 
035 |a (DE-599)NLM30338738 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Carpenter, Richard L 
245 1 0 |a HSF1 as a Cancer Biomarker and Therapeutic Target  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Revised 08.10.2019 
500 |a published: Print 
500 |a Citation Status In-Data-Review 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. 
520 |a Heat shock factor 1 (HSF1) was discovered in 1984 as the master regulator of the heat shock response. In this classical role, HSF1 is activated following cellular stresses such as heat shock that ultimately lead to HSF1-mediated expression of heat shock proteins to protect the proteome and survive these acute stresses. However, it is now becoming clear that HSF1 also plays a significant role in several diseases, perhaps none more prominent than cancer. HSF1 appears to have a pleiotropic role in cancer by supporting multiple facets of malignancy including migration, invasion, proliferation, and cancer cell metabolism among others. Because of these functions, and others, of HSF1, it has been investigated as a biomarker for patient outcomes in multiple cancer types. HSF1 expression alone was predictive for patient outcomes in multiple cancer types but in other instances, markers for HSF1 activity were more predictive. Clearly, further work is needed to tease out which markers are most representative of the tumor promoting effects of HSF1. Additionally, there have been several attempts at developing small molecule inhibitors to reduce HSF1 activity. All of these HSF1 inhibitors are still in preclinical models but have shown varying levels of efficacy at suppressing tumor growth. The growth of research related to HSF1 in cancer has been enormous over the last decade with many new functions of HSF1 discovered along the way. In order for these discoveries to reach clinical impact, further development of HSF1 as a biomarker or therapeutic target needs to be continued 
611 2 7 |a Journal Article  |2 gnd 
655 7 |a EMT  |2 gnd 
655 7 |a HSF1  |2 gnd 
655 7 |a biomarker  |2 gnd 
655 7 |a invasion  |2 gnd 
655 7 |a metastasis  |2 gnd 
655 7 |a migration  |2 gnd 
655 7 |a therapy.  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a EMT 
689 1 1 |a HSF1 
689 1 2 |a biomarker 
689 1 3 |a invasion 
689 1 4 |a metastasis 
689 1 5 |a migration 
689 1 6 |a therapy. 
689 1 |5 DE-601 
700 1 |a Gökmen-Polar, Yesim 
773 0 8 |i in  |t Current cancer drug targets  |g Vol. 19, No. 7 (2019), p. 515-524  |q 19:7<515-524  |w (DE-601)NLM120493810  |x 1873-5576 
856 4 1 |u http://dx.doi.org/10.2174/1568009618666181018162117  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 19  |j 2019  |e 7  |h 515-524